摘要
肿瘤化疗导致的中性粒细胞减少是化疗常见的血液学不良事件和剂量限制性不良反应。化疗导致的中性粒细胞减少有可能导致化学药物减量或延迟、粒细胞减少性发热和严重的感染,从而增加治疗费用、降低化疗效果、甚至会导致危及生命的并发症。因此,正确评估患者发生中性粒细胞减少的风险,早期识别粒细胞减少性发热和感染并进行合理的预防和治疗,对减少化疗所致中性粒细胞减少相关并发症、提高患者治疗安全及抗肿瘤化学治疗的疗效等方面具有重要意义。基于循证医学证据和专家共识,中国抗癌协会肿瘤临床化疗专业委员会和中国抗癌协会肿瘤支持治疗专业委员会制定了《中国肿瘤化疗导致的中性粒细胞减少诊治专家共识(2023版)》,在《肿瘤化疗导致的中性粒细胞减少的诊治专家共识(2019版)》的基础上进行了更新,旨在为我国肿瘤学医师提供关于化疗导致的中性粒细胞减少诊断和治疗有效的建议与参考。
Chemotherapy-induced neutropenia(CIN)is a common hematological adverse events and dose-limiting toxicities of chemotherapy.CIN may lead to dose reduction and delay of chemotherapeutic agents,febrile neutropenia and severe infection,which results in increased treatment cost,reduced efficacy of chemotherapy,and even life-threatening morbidities.Assessment of risk of CIN,early detection of FN and infection,and proper prevention and treatment play a crucial role in reducing the occurrence of CIN-related morbidities,improving patient treatment safety and anticancer efficacy.Based on evidence and expert opinion,the expert committee of Chinese Anti-Cancer Association issued"the consensus on diagnosis and treatment of chemotherapy-induced neutropenia in China(2023 edition)",which is an update version of the 2019 edition,aiming to provide reference for the diagnosis and treatment of CIN for Chinese oncologists.
作者
中国抗癌协会肿瘤临床化疗专业委员会
中国抗癌协会肿瘤支持治疗专业委员会
冯继锋
石远凯
沈波
China Anti-Cancer Association Tumor Clinical Chemotherapy Professional Committee;China Anti-Cancer Association Tumor Support Therapy Professional Committee;Feng Jifeng;Shi Yuankai;Shen Bo(不详;Department of Oncology,the Affiliated Cancer Hospital of Nanjing Medical University&Jiangsu Cancer Hospital,Nanjing 210009,China;Dpartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Bejing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China;Day Treatment Center,the Afiliated Cancer Hospital of Nanjing Medical University&Jiangsu Cancer Hospital,Nanjing 210009,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2023年第7期575-583,共9页
Chinese Journal of Oncology
